{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:17:25Z","timestamp":1760782645182,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1124\/jpet.103.064782","type":"journal-article","created":{"date-parts":[[2004,8,21]],"date-time":"2004-08-21T05:57:29Z","timestamp":1093067849000},"page":"1171-1182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["SL25.1131 [3(S),3 a(S)-3-Methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3 a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a New, Reversible, and Mixed Inhibitor of Monoamine Oxidase-A and Monoamine Oxidase-B: Biochemical and Behavioral Profile"],"prefix":"10.1016","volume":"310","author":[{"given":"N.","family":"Aubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barneoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Caille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sontag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Marc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lolivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Perron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Le Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Charieras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Puech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jegham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Scatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Curet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.064782_bib1","unstructured":"Agid Y, Javoy-Agid F, and Ruberg M (1995) Biochemistry of neurotransmitters in Parkinson\u2019s disease, in Blue Books of Practical Neurology, Movement Disorders 1 and 2 (Marsden CD and Fahn S eds) pp 166-230, Butterworth Heinemann, London, UK."},{"key":"10.1124\/jpet.103.064782_bib2","doi-asserted-by":"crossref","unstructured":"Aubin N, Curet O, Deffois A, and Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71: 1635-1642.","DOI":"10.1046\/j.1471-4159.1998.71041635.x"},{"key":"10.1124\/jpet.103.064782_bib3","doi-asserted-by":"crossref","unstructured":"Barneoud P, Descombris E, Aubin N, and Abrous DN (2000), Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system. Eur J Neurosci 12: 322-336.","DOI":"10.1046\/j.1460-9568.2000.00896.x"},{"key":"10.1124\/jpet.103.064782_bib4","unstructured":"Bieck PR and Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 28: 21-31."},{"key":"10.1124\/jpet.103.064782_bib5","doi-asserted-by":"crossref","unstructured":"Birkmayer W, Knoll J, Riederer P, and Youdim MBH (1983) (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson\u2019s disease. Mod Probl Pharmacopsychiatry 19: 170-176.","DOI":"10.1159\/000407513"},{"key":"10.1124\/jpet.103.064782_bib6","doi-asserted-by":"crossref","unstructured":"Boudier C and Bieth JG (1989) Mucus proteinase inhibitor: a fast-acting inhibitor of leucocyte elastase. Biochim Biophys Acta 995: 36-41.","DOI":"10.1016\/0167-4838(89)90230-6"},{"key":"10.1124\/jpet.103.064782_bib7","doi-asserted-by":"crossref","unstructured":"Braestrup C, Andersen H, and Randrup A (1975) The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behavior in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34: 181-187.","DOI":"10.1016\/0014-2999(75)90238-1"},{"key":"10.1124\/jpet.103.064782_bib8","doi-asserted-by":"crossref","unstructured":"Butcher SP, Fairbrother IS, Kelly JS, and Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981-988.","DOI":"10.1111\/j.1471-4159.1990.tb04587.x"},{"key":"10.1124\/jpet.103.064782_bib9","doi-asserted-by":"crossref","unstructured":"Caille D, Bergis O, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, and Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 277: 265-277.","DOI":"10.1016\/S0022-3565(25)12818-8"},{"key":"10.1124\/jpet.103.064782_bib10","unstructured":"Chase TN, Engber TM, and Mouradian MM (1993) Sriatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson\u2019s disease. Adv Neurol 60: 181-185."},{"key":"10.1124\/jpet.103.064782_bib11","doi-asserted-by":"crossref","unstructured":"Cotzias GC, Papavasiliou PS, and Gellene R (1969) Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med 280: 337-345.","DOI":"10.1056\/NEJM196902132800701"},{"key":"10.1124\/jpet.103.064782_bib12","doi-asserted-by":"crossref","unstructured":"Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, and Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277: 253-264.","DOI":"10.1016\/S0022-3565(25)12817-6"},{"key":"10.1124\/jpet.103.064782_bib13","doi-asserted-by":"crossref","unstructured":"Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, and Scatton B (1998) Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord 51: 287-303.","DOI":"10.1016\/S0165-0327(98)00225-0"},{"key":"10.1124\/jpet.103.064782_bib14","doi-asserted-by":"crossref","unstructured":"Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, and Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 400-414.","DOI":"10.1016\/S0022-3565(25)23665-5"},{"key":"10.1124\/jpet.103.064782_bib15","unstructured":"Fahn S (1996) Controversies in the therapy of Parkinson\u2019s disease. Adv Neurol 69: 477-486."},{"key":"10.1124\/jpet.103.064782_bib16","doi-asserted-by":"crossref","unstructured":"Fahn S and Chouinard S (1998) Experience with tranylcypromine in early Parkinson\u2019s disease. J Neural Transm Suppl 52: 49-61.","DOI":"10.1007\/978-3-7091-6499-0_6"},{"key":"10.1124\/jpet.103.064782_bib17","doi-asserted-by":"crossref","unstructured":"Heeringa MJ, D\u2019Agostini F, DeBoer P, Da Prada M, and Damsma G (1997) Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior. J Neural Transm 104: 593-603.","DOI":"10.1007\/BF01291878"},{"key":"10.1124\/jpet.103.064782_bib18","doi-asserted-by":"crossref","unstructured":"Heikkila RE, Hess A, and Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science (Wash DC) 224: 1451-1453.","DOI":"10.1126\/science.6610213"},{"key":"10.1124\/jpet.103.064782_bib19","doi-asserted-by":"crossref","unstructured":"Hughes AJ (1997) Drug treatment of Parkinson\u2019s disease in the 1990s. Achievements and future possibilities. Drugs 53: 195-205.","DOI":"10.2165\/00003495-199753020-00002"},{"key":"10.1124\/jpet.103.064782_bib20","doi-asserted-by":"crossref","unstructured":"Jacobs BL (1976) An animal behavior model for studying central serotonergic synapses. Life Sci 19: 777-785.","DOI":"10.1016\/0024-3205(76)90303-9"},{"key":"10.1124\/jpet.103.064782_bib21","doi-asserted-by":"crossref","unstructured":"Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285-1297.","DOI":"10.1016\/0006-2952(68)90066-X"},{"key":"10.1124\/jpet.103.064782_bib22","doi-asserted-by":"crossref","unstructured":"Kan JP, Steinberg R, Mouget-Goniot C, Worms P, and Biziere K (1987) SR95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J Pharmacol Exp Ther 240: 251-258.","DOI":"10.1016\/S0022-3565(25)22705-7"},{"key":"10.1124\/jpet.103.064782_bib23","unstructured":"Knoll J and Magyar K (1972) Some puzzling pharmacological effects of monoamines oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393-408."},{"key":"10.1124\/jpet.103.064782_bib24","unstructured":"Koller WC and Pahwa R (1994) Treating motor fluctuations with controlled-release levodopa preparations. Neurology 44(7 Suppl 6): S23-S28."},{"key":"10.1124\/jpet.103.064782_bib25","doi-asserted-by":"crossref","unstructured":"Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, and Yoo K (1997) Tolcapone improves motor function and reduces levodopa requirements in patients with Parkinson\u2019s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48: 81-87.","DOI":"10.1212\/WNL.48.1.81"},{"key":"10.1124\/jpet.103.064782_bib26","doi-asserted-by":"crossref","unstructured":"Lang AE and Lozano AM (1998a) Parkinson\u2019s disease. First of two parts. N Engl J Med 339: 1044-1053.","DOI":"10.1056\/NEJM199810083391506"},{"key":"10.1124\/jpet.103.064782_bib27","doi-asserted-by":"crossref","unstructured":"Lang AE and Lozano AM (1998b) Parkinson\u2019s disease. Second of two parts. N Engl J Med 339: 1130-1143.","DOI":"10.1056\/NEJM199810153391607"},{"key":"10.1124\/jpet.103.064782_bib28","doi-asserted-by":"crossref","unstructured":"Lessin AW (1959) The pharmacological evaluation of monoamine oxidase inhibitors. Biochem Pharmacol 2: 290-298.","DOI":"10.1016\/0006-2952(59)90043-7"},{"key":"10.1124\/jpet.103.064782_bib29","doi-asserted-by":"crossref","unstructured":"Marks MJ, Romm E, Bealer SM, and Collins AC (1985) A test battery for measuring nicotine effects in mice. Pharmacol Biochem Behav 23: 325-330.","DOI":"10.1016\/0091-3057(85)90577-5"},{"key":"10.1124\/jpet.103.064782_bib30","doi-asserted-by":"crossref","unstructured":"Metman LV, Van den Munckhof P, Klaassen AA, Blanchet P, Mouradian MM, and Chase TN (1997) Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson\u2019s disease. Neurology 49: 711-713.","DOI":"10.1212\/WNL.49.3.711"},{"key":"10.1124\/jpet.103.064782_bib31","doi-asserted-by":"crossref","unstructured":"Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors. Biochim Biophys Acta 185: 269-286.","DOI":"10.1016\/0005-2744(69)90420-3"},{"key":"10.1124\/jpet.103.064782_bib32","doi-asserted-by":"crossref","unstructured":"Ortmann R, Shaub M, Felner A, Lauber J, Christen P, and Waldmeier PC (1984) Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84: 22-27.","DOI":"10.1007\/BF00432018"},{"key":"10.1124\/jpet.103.064782_bib33","doi-asserted-by":"crossref","unstructured":"Ortmann R, Waldmeier PC, Radeke E, Felner A, and Delini-Stula A (1980) The effects of 5-HT uptake and MAO-inhibitors on L-5-HTP-induced excitation in rat. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 311: 185-192.","DOI":"10.1007\/BF00510258"},{"key":"10.1124\/jpet.103.064782_bib34","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1996a) Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37-45.","DOI":"10.1002\/ana.410390107"},{"key":"10.1124\/jpet.103.064782_bib35","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1996b) Effect of lazabemide on the progression of disability in early Parkinson\u2019s disease. Ann Neurol 40: 99-109.","DOI":"10.1002\/ana.410400116"},{"key":"10.1124\/jpet.103.064782_bib36","doi-asserted-by":"crossref","unstructured":"Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, and Youdim MBH (1995) The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson\u2019s disease. J Clin Psychopharmacol 15(4 Suppl 2): 51S-59S.","DOI":"10.1097\/00004714-199508001-00010"},{"key":"10.1124\/jpet.103.064782_bib37","doi-asserted-by":"crossref","unstructured":"Strolin-Benedetti M and Dostert P (1985) Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci 6: 246-251.","DOI":"10.1016\/0165-6147(85)90116-6"},{"key":"10.1124\/jpet.103.064782_bib38","doi-asserted-by":"crossref","unstructured":"Sundstrom E, Stromberg I, Tsutsumi T, Olson L, and Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the central catecholamine neurons in C57BL\/6 mice. Comparison with three other strains of mice. Brain Res 405: 26-38.","DOI":"10.1016\/0006-8993(87)90986-3"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524315459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524315459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.064782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:59:12Z","timestamp":1739998752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524315459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0022356524315459"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.064782","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SL25.1131 [3(S),3 a(S)-3-Methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3 a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a New, Reversible, and Mixed Inhibitor of Monoamine Oxidase-A and Monoamine Oxidase-B: Biochemical and Behavioral Profile","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.064782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}